(Press-News.org) CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Investigators further found that pacritinib could be used safely in patients with myelofibrosis who have thrombocytopenia, a life-threating loss of blood platelets that can lead to deadly bleeding. The only currently approved therapy for myelofibrosis -- ruxolitinib -- is not recommended in patients who have severe thrombocytopenia.
Ruben A. Mesa, M.D., chair of hematology and medical oncology at Mayo Clinic in Arizona, will present these results at a press conference held during the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
'Use of pacritinib can alleviate the burden and diminish the suffering that this cancer causes,' says Mesa. 'For many of the patients who used it, pacritinib is a very good drug. The agent was significantly superior to other medical treatments.
'It is too early to know if pacritinib has an impact on survival, but that is clearly our expectation,' he adds.
Mayo researchers led by Mesa were also part of a phase II trial that found pacritinib offered significant benefit in treating the disorder.
Myelofibrosis is a chronic bone-marrow disorder that can lead to lowering of blood counts, scarring in the bone marrow, severe symptoms and enlargement of the spleen. Myelofibrosis can be life threatening for afflicted patients because of the debilitation the disease causes and/or progression to acute leukemia, Mesa says.
Myelofibrosis is one of three blood cancers classified as myeloproliferative neoplasms (MPNs), and MPN affects about 350,000 people in the U.S., he says.
In this study, two-thirds of the 327 patients with primary and secondary myelofibrosis were treated with pacritinib. The other one-third were treated with best available therapy (BAT), but were able to cross over to use of pacritinib if their cancer was largely nonresponsive. BAT was chosen by the patient's physician, but did not include ruxolitinib because many patients were not eligible for it due to existing thrombocytopenia.
Pacritinib, an oral drug, is known as a JAK2/FLT3 inhibitor. JAK2 is a protein that acts like an on-off growth switch in blood cells.
'The JAK2 pathway is abnormally turned on in patients, which leads to this chronic leukemia. This drug turns off that switch,' Mesa says.
PERSIST-1 investigators found that medium duration of treatment on the study was 16-plus months, and that by six months, spleen size was reduced in 25 percent of evaluable patients treated with pacritinib compared to 6 percent in the BAT group. Almost 80 percent of BAT patients crossed over to use of pacritinib, and 21 percent of all pacritinib patients had achieved a reduction in spleen volume of 35 percent or more. Symptoms of the cancer were reduced in more than 46 percent of pacritinib-treated patients compared to 9 percent in patients given BAT.
Researchers also found that 25 percent of patients who needed blood transfusions at the beginning of the trial were able to stop the transfusions.
'This is a very favorable observation,' says Mesa.
INFORMATION:
The research team included investigators from the U.S., Hungary, Russia, Australia, New Zealand, France, the Netherlands, Italy, Belgium, Germany and the United Kingdom.
The study was funded by CTI Biopharma.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.com or newsnetwork.mayoclinic.org.
Contact:
Joe Dangor
dangor.yusuf@mayo.edu
507-284-5005
Mayo Clinic
CHICAGO -- Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.
Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone.
The announcement was made at ...
Alexandria, VA - As this summer's blockbuster movie season gets underway, EARTH Magazine asks an important question: In movies, "are geologists portrayed as heroes or villains?" The topic of how geologists are portrayed in film has been oft-debated around a campfire, or over a frosty beverage at the end of a day of fieldwork, but now four scientists bring some serious analysis to the subject in the June issue feature, "Rock Stars - Geologists on the Silver Screen."
The authors - all geologists in the Department of Earth Sciences at the University of Gothenburg in Sweden ...
Hercules, CA -- May 29, 2015 -- Researchers at Harvard Medical School and the Digital Biology Center at Bio-Rad Laboratories, Inc. have developed a rapid, scalable, and cost-effective method for chromosomal phasing that provides researchers with a new method to determine if genetic variants are linked on the same chromosome. Using Bio-Rad's Droplet Digital PCR (ddPCRTM) technology, the Drop-Phase method can rapidly determine the chromosomal phase of allelic markers hundreds of kilobases apart. This ability may provide new insights into the cause, penetrance, and severity ...
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
Results of the trial with pembrolizumab, marketed as Keytruda, ...
The recent floods in Texas have caused some of the worst flooding since Hurricane Ike in 2008, causing the rainiest month in the state's history.
What lessons have been learned from Ike's devastation of the Galveston and Houston area, and how have they helped in the prediction of future such storms?
Researchers at the Institute for Computational Engineering and Sciences at the University of Texas at Austin have been studying computational models and simulations of hurricanes like Ike in order to predict the consequences of such natural disasters and better prepare ...
PHOENIX -- If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined.
In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.
One of the most common reasons people ...
At a traditional stone-laying ceremony outside La Serena, Chile on April 14th, construction officially began of the Large Synoptic Survey Telescope (LSST). This ambitious international astrophysics project is slated to start scanning the heavens in 2022. When it does, LSST should open up the "dark universe" of dark matter and dark energy--the unseen substance and force, respectively, composing 95 percent of the universe's mass and energy--as never before.
On April 2, 2015, the Director of LSST, Steven Kahn, along with astrophysicist Sarah Bridle and theoretical physicist ...
The study, published May 29 in the open access Nature Publishing Group journal Scientific Reports, reveals a direct link between the main culprit of Alzheimer's disease and memory loss.
Alzheimer's disease is characterized by the formation of amyloid plaques in the brain tissue. These amyloid plaques are made up of an insoluble protein, 'Amyloid-beta' (Abeta), which forms small structures called 'oligomers' that are important in the disease progression.
Although these proteins are known to be involved in Alzheimer's, little is understood about how they lead to memory ...
Stanford University scientists have created a new carbon material that significantly boosts the performance of energy-storage technologies. Their results are featured on the cover of the journal ACS Central Science.
"We have developed a 'designer carbon' that is both versatile and controllable," said Zhenan Bao, the senior author of the study and a professor of chemical engineering at Stanford. "Our study shows that this material has exceptional energy-storage capacity, enabling unprecedented performance in lithium-sulfur batteries and supercapacitors."
According to ...
One of the main health targets proposed by the UN Sustainable Development Goals (SDG) is to reduce by one-third premature mortality from non-communicable diseases such as cancer, stroke and dementia. The goals for 2016-2030 define premature mortality as deaths occurring among people aged 69 years old or younger.
The proposed SDG target sends an unambiguous statement to UN member states that health provision for younger groups must be prioritised at the expense of people aged 70 or more, according to the international group of signatories of the letter published in The ...
